Stock Ratings / Health Care / PBM / dividends

MCRB (40) ACTU (35) KYNB (32) NEUP (31) ⌘ Pro Terminal →

Psyence Biomedical Ltd. (PBM) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.31 -8.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.25

Psyence Biomedical Ltd. (PBM) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $17.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PBM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PBM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Psyence Biomedical Ltd. (NASDAQ: PBM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $3.31 (-8.31% 1D, market cap $17.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PBM ranks #344 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PBM compare to MCRB and ACTU in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBM carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MCRB (Seres Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $17.8M) and ACTU (Actuate Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.4M). Among the 5-stock peer group, PBM leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PBM?

▼

For Psyence Biomedical Ltd. (PBM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #344 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.25 (-1.69%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY PBM SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($492.7K FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$4.55-6.8% Next Q

Q2 (-2Q)

Grade C-$4.24-29% Next Q

Q3 (-1Q)

Grade D$3.01+10% Next Q

Current

Grade D$3.31-6.1% Hist 90D α

Trajectory: C- (54) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PBM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PBM currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.79) and Max Pain ($3.48) forces dealer call-delta covering toward $128.99.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PBM Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PBM)

✓Walkthrough of PBM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PBM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.52%▲ ASCENDING TRIANGLE

2026-11-03O $3.61H $3.61L $3.31C $3.31VOL 46.6K

SUP: $2.70SMA50: $4.79SMA200: $3.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PBM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PBM Butterfly Map → + Track PBM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PBM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PBM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PBM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBM)

Health Care Rank #344 of 1016 ⚔️ MCRB vs PBM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PBM vs. MCRB, ACTU, KYNB, NEUP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Psyence Biomedical Ltd. (PBM) ranks #344 by composite RQD confidence (46/100, grade D) and #838 by equity capitalization ($17.6M). Within this direct 5-issuer industry benchmark cohort, PBM leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. PBM currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PBM ACTIVE Psyence Biomedical Ltd.	D	46/100	—	—	—	-8.31%	$17.6M	Benchmark Subject
MCRB Seres Therapeutics Inc.	D-	40/100	—	—	-35.0%	-9.23%	$17.8M	/mcrb-vs-pbm →
ACTU Actuate Therapeutics Inc.	D-	35/100	—	—	-35.0%	-9.68%	$18.4M	/actu-vs-pbm →
KYNB Kyntra Bio Inc.	E	32/100	—	91.4%	-35.0%	-1.72%	$18.5M	/kynb-vs-pbm →
NEUP Neuphoria Therapeutics Inc.	E	31/100	—	—	-11.8%	-0.33%	$16.5M	/neup-vs-pbm →

2. PBM Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Psyence Biomedical Ltd. (PBM) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $17.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. PBM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PBM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PBM compare to MCRB and ACTU in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PBM?

Where is PBM trading relative to its 50-day, 200-day, and 52-week technical levels?

PBM last traded at $3.31 (-8.31% on volume of 46,640 shares), positioning the stock -30.90% below its 50-day simple moving average ($4.79) and -16.83% below its 200-day simple moving average ($3.98). Across its 52-week range of $1.92 to $122.85, PBM sits at the 1.1% percentile with a 14-day RSI of 37.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.90 to $3.72).

PBM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does PBM pay a dividend and is it safe?

Psyence Biomedical Ltd. (PBM) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: PBM RQD Cockpit PBM 12M Forecast PBM Earnings & Move PBM Dividends & DRIP PBM Insiders & 13F PBM Whale Options PBM Profit Sankey PBM News & Why

ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PBM — Psyence Biomedical Ltd.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:19:50Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PBM scores 46 out of 100, a D grade under the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars break down as follows:

Fundamental Cash Engine: 12 / 20. Per the Roarable RQD rating, ROIC is 0% and FCF yield is 0%. The cash-generation pillar offers little support, so the investment case does not rest on current earnings power.
Whale 13F Flow: 3 / 20. Per the Roarable RQD rating, this pillar measures institutional accumulation and options positioning. It is the weakest pillar, indicating limited smart-money support in the source data.
Insider Conviction: 9 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The score is below midpoint, indicating weak insider conviction.
Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0 and sector sensitivity is reflected here. The pillar is below midpoint, so market-regime tailwinds are not a clear offset.
Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar, though still only moderate.

For a prospective investor, the pillar profile points to a stock whose balance sheet is the most defensible element while cash generation, institutional support, and insider conviction are all weak. Valuation cannot be assessed on earnings because P/E and EPS are not available in source data. The stock's 52-week range of $1.92 to $128.91 per the market data indicates extreme historical volatility, which should be weighed against the current price. Upside would require a catalyst that shifts institutional or insider sentiment; the source data contains only modest signals of that kind.

Business

Psyence Biomedical Ltd. (PBM) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations, per the company profile. Per the recent news wire, the company has invested in PsyLabs and entered a partnership with DEA-registered Benuvia, and a headline references an ibogaine manufacturing deal. Not available in source data for product detail, customer base, or revenue model beyond these references.

Recent Catalysts & News Wire Analysis

Catalyst (GREEN): A news item titled as a catalyst notes that an ibogaine manufacturing deal helps unlock PBM's additional PsyLabs investment.
Catalyst (GREEN): A Kalkine report references a pre-market gain of 6.76% on October 29.
Catalyst (GREEN): A GlobeNewswire release reports that PsyBio partners with DEA-registered Benuvia.
Market wire (YELLOW): Investing.com Canada reports an investment of $2.6m in PsyLabs after milestones were met.
Market wire (YELLOW): Benzinga lists PBM among health care stocks moving in pre-market trading.
Market wire (YELLOW): A Simply Wall St stock analysis covers market action and institutional positioning.

Risk watch items: the source data contains no proprietary signals and no supply-chain links, so catalyst assessment depends entirely on news headlines. Per the market data, volume was 62,146 with a 6.18% price change.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from source data. The only sector context available is Health Care / Biotechnology: Pharmaceutical Preparations per the profile. Investors should note that the news-linked PsyLabs and Benuvia relationships are the only ecosystem references in the source, and their operational dependencies are not documented.

Open Questions

What are the reported revenue, operating income, net income, and cash flow figures, given that the financials section is empty?
What are the P/E, EPS, and EV/EBITDA values, which are all absent from the market data?
What is the scope and financial exposure of the PsyLabs investment and the Benuvia partnership?
Who are the institutional and insider holders, and what is their recent trading activity?
What explains the 52-week range of $1.92 to $128.91, and what drove the price swing?

PBM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Psyence Biomedical Ltd. (PBM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PBM Debate Forum (3) ↓

🟡 MARKET WIRE Simply Wall St • 18h ago

Psyence Biomedical (Nasdaq:PBM) - Stock Analysis

Simply Wall St report covering Psyence Biomedical Ltd. (PBM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 21h ago

An ibogaine manufacturing deal helps unlock Psyence Biomedical (PBM)'s additional PsyLabs investment.

Stock Titan report covering Psyence Biomedical Ltd. (PBM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga report covering Psyence Biomedical Ltd. (PBM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 1d ago

Psyence Biomedical invests $2.6m in PsyLabs after milestones met By Investing.com

Investing.com Canada report covering Psyence Biomedical Ltd. (PBM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Kalkine • 1d ago

Why Did Psyence Biomedical (NASDAQ:PBM) Gain 6.76% in Pre-Market Trading on October 29?

Kalkine report covering Psyence Biomedical Ltd. (PBM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GlobeNewswire • 1d ago

Psyence BioMed Partners with DEA-Registered Benuvia

GlobeNewswire report covering Psyence Biomedical Ltd. (PBM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Psyence Biomedical Ltd. (PBM) Stock Price Prediction for 2026, 2030-2040

Traders Union report covering Psyence Biomedical Ltd. (PBM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 4d ago

'New Bill In Congress Would Dramatically Overhaul How The Federal Government Classifies Drugs While Legalizing Marijuana' - Marijuana Moment

https://www.marijuanamoment.net/new-bill-in-congress-would-dramatically-overhaul-how-the-federal-government-classifies-drugs-while-legalizing-marijuana/

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PBM Bull vs. Bear Conversation Board — What's Your Call at $3.31?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PBM 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $3.90 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PBM (D • RQD 46/100) a Buy at $3.61?

Welcome to the PBM (Psyence Biomedical Ltd.) Roar Pit. Current RQD Composite is 46/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.74 (-24.1%)

Spot @ $3.61

Pump the brakes on PBM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PBM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Psyence Biomedical Ltd. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.58 (+26.9%)

Spot @ $3.61

PBM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PBM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $3.61 (52-wk range $1.92 - $128.91), any beat on forward guidance forces shorts and underweight funds to chase.